Cargando…

Development of oral immunomodulatory agents in the management of multiple sclerosis

The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicholas, Richard, Giannetti, Paolo, Alsanousi, Ali, Friede, Tim, Muraro, Paolo A
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100222/ https://www.ncbi.nlm.nih.gov/pubmed/21625416 http://dx.doi.org/10.2147/DDDT.S10498

Ejemplares similares

Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents
por: Girouard, Nathalie, et al.
Publicado: (2011)

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
por: Nicholas, Jacqueline Ann, et al.
Publicado: (2014)

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale–29
por: Raffel, Joel, et al.
Publicado: (2017)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Antibody-mediated cell depletion therapies in multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review
por: Furgiuele, Alessia, et al.
Publicado: (2021)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis
por: Colasanti, Alessandro, et al.
Publicado: (2016)

Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2019)

Intrathecal T‐cell clonal expansions in patients with multiple sclerosis
por: de Paula Alves Sousa, Alessandra, et al.
Publicado: (2016)

Mobile health interventions in multiple sclerosis: A systematic review
por: Heesen, Christoph, et al.
Publicado: (2023)

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
por: Gasperini, Claudio, et al.
Publicado: (2012)

Phytochemicals as Immunomodulatory Agents in Melanoma
por: Tabolacci, Claudio, et al.
Publicado: (2023)

Immunomodulatory and anti-inflammatory effects of probiotics in multiple sclerosis: a systematic review
por: Morshedi, Mohammad, et al.
Publicado: (2019)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances
por: Mariottini, Alice, et al.
Publicado: (2023)

Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells in Multiple Sclerosis Patients With Older Appearing Brains
por: Jacobs, Sophie A. H., et al.
Publicado: (2022)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Nutrition Facts in Multiple Sclerosis
por: Riccio, Paolo, et al.
Publicado: (2015)

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
por: Ostkamp, Patrick, et al.
Publicado: (2021)

The Potential of Frog Skin-Derived Peptides for Development into Therapeutically-Valuable Immunomodulatory Agents
por: Pantic, Jelena M., et al.
Publicado: (2017)

Development of Broad-Spectrum Antiviral Agents—Inspiration from Immunomodulatory Natural Products
por: Zhang, Mengxun, et al.
Publicado: (2021)

Bacterial flagellin—a potent immunomodulatory agent
por: Hajam, Irshad A, et al.
Publicado: (2017)

Fructans as Immunomodulatory and Antiviral Agents: The Case of Echinacea
por: Dobrange, Erin, et al.
Publicado: (2019)

COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology
por: Değirmenci, Mehmet Fatih Kağan, et al.
Publicado: (2021)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Adjunctive therapies and immunomodulatory agents in the management of severe influenza
por: Hui, David S., et al.
Publicado: (2013)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis
por: Baharlooi, Hussein, et al.
Publicado: (2022)

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease
por: Martinez, Bridget, et al.
Publicado: (2018)

Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
por: Dziedzic, Angela, et al.
Publicado: (2020)

Immunomodulatory drugs: Oral and systemic adverse effects
por: Bascones-Martinez, Antonio, et al.
Publicado: (2014)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

The Gas6/TAM System and Multiple Sclerosis
por: Bellan, Mattia, et al.
Publicado: (2016)

Intrathecal Inflammation in Progressive Multiple Sclerosis
por: Monaco, Salvatore, et al.
Publicado: (2020)

Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis
por: Elyaman, Wassim, et al.
Publicado: (2011)

The role of adjuvant immunomodulatory agents for treatment of severe influenza
por: Hui, David S., et al.
Publicado: (2018)

Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions
por: Bishop, Courtney A, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_712qqedh9fm3rjdo2q7hfoklam